BioAtla Investor Presentation Deck

Phase 1 results with CAB-ROR2 (BA3021) support advancing into Phase 2 in multiple indications ROR2+ Tumor Types NSCLC Melanoma SCCHN bicatla Results ▪ Partial response in 2 / 3 patients who previously experienced failure on PD-1 and who received Phase 2 dose or higher ▪ Complete response in 1 / 1 patient who previously experienced failure on PD-1 Clearance of pulmonary metastases followed by normalization of adenopathy Continued complete response off treatment for over 2 years ■ ■ Partial response in 1 / 1 ROR2+ refractory to four prior lines of therapy including cetuximab and PD-1 (pembrolizumab) Promising safety and tolerability profile across multiple tumor types No ROR2 ADC or small molecules in the clinic to date, suggesting CAB-ROR2-ADC is a first-in-class therapy across multiple tumor types BioAtla| Overview 48

View entire presentation